BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 9308887)

  • 1. Homologous and heterologous protein-protein interactions of human DNA topoisomerase IIalpha.
    Kroll DJ
    Arch Biochem Biophys; 1997 Sep; 345(2):175-84. PubMed ID: 9308887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone.
    Harker WG; Slade DL; Parr RL; Holguin MH
    Cancer Res; 1995 Nov; 55(21):4962-71. PubMed ID: 7585537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence determinants of nuclear localization in the alpha and beta isoforms of human topoisomerase II.
    Mirski SE; Gerlach JH; Cole SP
    Exp Cell Res; 1999 Sep; 251(2):329-39. PubMed ID: 10471318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of human DNA topoisomerase IIalpha with mitotic chromosomes in mammalian cells is independent of its catalytic activity.
    Mo YY; Beck WT
    Exp Cell Res; 1999 Oct; 252(1):50-62. PubMed ID: 10502399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cytochrome b5 tail anchors and stabilizes subdomains of human DNA topoisomerase II alpha in the cytoplasm of retrovirally infected mammalian cells.
    Soltermann A; Ernst A; Leroy D; Stahel RA; Gasser SM
    Exp Cell Res; 1999 Jun; 249(2):308-19. PubMed ID: 10366430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional compatibility between isoform alpha and beta of type II DNA topoisomerase.
    Sakaguchi A; Kikuchi A
    J Cell Sci; 2004 Mar; 117(Pt 7):1047-54. PubMed ID: 14996935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
    Chen M; Beck WT
    Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of DNA topoisomerase II alpha/beta heterodimers in HeLa cells.
    Gromova I; Biersack H; Jensen S; Nielsen OF; Westergaard O; Andersen AH
    Biochemistry; 1998 Nov; 37(47):16645-52. PubMed ID: 9843432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.
    Zhou Z; Zwelling LA; Kawakami Y; An T; Kobayashi K; Herzog C; Kleinerman ES
    Cancer Res; 1999 Sep; 59(18):4618-24. PubMed ID: 10493516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucose-regulated stresses cause degradation of DNA topoisomerase IIalpha by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells.
    Kim HD; Tomida A; Ogiso Y; Tsuruo T
    J Cell Physiol; 1999 Jul; 180(1):97-104. PubMed ID: 10362022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human topoisomerase IIalpha and IIbeta interact with the C-terminal region of p53.
    Cowell IG; Okorokov AL; Cutts SA; Padget K; Bell M; Milner J; Austin CA
    Exp Cell Res; 2000 Feb; 255(1):86-94. PubMed ID: 10666337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the human topoisomerase IIbeta (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites.
    Lok CN; Lang AJ; Mirski SE; Cole SP
    Biochem J; 2002 Dec; 368(Pt 3):741-51. PubMed ID: 12197834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel point mutation in the 3' flanking region of the DNA-binding domain of topoisomerase II alpha associated with acquired resistance to topoisomerase II active agents.
    Hashimoto S; Danks MK; Chatterjee S; Beck WT; Berger NA
    Oncol Res; 1995; 7(1):21-9. PubMed ID: 7549041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear interactions of topoisomerase II alpha and beta with phospholipid scramblase 1.
    Wyles JP; Wu Z; Mirski SE; Cole SP
    Nucleic Acids Res; 2007; 35(12):4076-85. PubMed ID: 17567603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-association and DNA binding properties of the human topoisomerase IIA alpha2HTH module.
    Morant-Lhomel A; René B; Zargarian L; Troalen F; Mauffret O; Fermandjian S
    Biochimie; 2006; 88(3-4):253-63. PubMed ID: 16213649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA topoisomerase IIalpha and -beta expression in human ovarian cancer.
    Withoff S; van der Zee AG; de Jong S; Hollema H; Smit EF; Mulder NH; de Vries EG
    Br J Cancer; 1999 Feb; 79(5-6):748-53. PubMed ID: 10070864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a potential regulatory role for inverted CCAAT boxes in the human topoisomerase II alpha promoter.
    Herzog CE; Zwelling LA
    Biochem Biophys Res Commun; 1997 Mar; 232(3):608-12. PubMed ID: 9126321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression.
    Hopfner R; Mousli M; Jeltsch JM; Voulgaris A; Lutz Y; Marin C; Bellocq JP; Oudet P; Bronner C
    Cancer Res; 2000 Jan; 60(1):121-8. PubMed ID: 10646863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural and functional analysis of the control region of the human DNA topoisomerase II alpha gene in drug-resistant cells.
    Takano H; Ise T; Nomoto M; Kato K; Murakami T; Ohmori H; Imamura T; Nagatani G; Okamoto T; Ohta R; Furukawa M; Shibao K; Izumi H; Kuwano M; Kohno K
    Anticancer Drug Des; 1999 Apr; 14(2):87-92. PubMed ID: 10405635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.